Business Description
Terns Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8808811074
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 904.81 | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4 | |||||
3-Year EPS without NRI Growth Rate | 10.4 | |||||
3-Year FCF Growth Rate | 10.9 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.91 | |||||
9-Day RSI | 59.45 | |||||
14-Day RSI | 59.29 | |||||
6-1 Month Momentum % | -6.69 | |||||
12-1 Month Momentum % | 23.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 21.02 | |||||
Quick Ratio | 21.02 | |||||
Cash Ratio | 20.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -41.6 | |||||
Shareholder Yield % | 0.08 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -38.56 | |||||
ROA % | -36.67 | |||||
ROIC % | -2084.85 | |||||
3-Year ROIIC % | 711.6 | |||||
ROC (Joel Greenblatt) % | -10876.88 | |||||
ROCE % | -43.31 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.44 | |||||
Price-to-Tangible-Book | 3.43 | |||||
EV-to-EBIT | -4.87 | |||||
EV-to-Forward-EBIT | -4.72 | |||||
EV-to-EBITDA | -4.91 | |||||
EV-to-Forward-EBITDA | -4.73 | |||||
EV-to-FCF | -6.66 | |||||
Price-to-Net-Current-Asset-Value | 3.45 | |||||
Price-to-Net-Cash | 3.52 | |||||
Earnings Yield (Greenblatt) % | -20.53 | |||||
FCF Yield % | -10.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Terns Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.224 | ||
Beta | -1.27 | ||
Volatility % | 80.3 | ||
14-Day RSI | 59.29 | ||
14-Day ATR (€) | 0.741017 | ||
20-Day SMA (€) | 7.355 | ||
12-1 Month Momentum % | 23.58 | ||
52-Week Range (€) | 3.035 - 10.2 | ||
Shares Outstanding (Mil) | 70.37 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Terns Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Terns Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Terns Pharmaceuticals Inc Frequently Asked Questions
What is Terns Pharmaceuticals Inc(FRA:430)'s stock price today?
When is next earnings date of Terns Pharmaceuticals Inc(FRA:430)?
Does Terns Pharmaceuticals Inc(FRA:430) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |